focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBARK.L Regulatory News (BARK)

  • There is currently no data for BARK

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cambridge Sleep Sciences partnership announcement

11 Mar 2021 07:00

RNS Number : 8710R
Barkby Group PLC (The)
11 March 2021
 

11 March 2021

 

The Barkby Group PLC

 

("Barkby" or the "Company")

 

New partnership explores the impact of sleep technology on Parkinson's

 

The Barkby Group is pleased to announce that its subsidiary, Cambridge Sleep Sciences, has signed a collaboration agreement with Parkinson's Concierge to help address sleep issues associated with Parkinson's Disease.

 

Sleep disturbance is common for those living with Parkinson's and can include such symptoms as drowsiness, fatigue, anxiety and other mental health problems. According to the Michael J. Fox Foundation, "many people with Parkinson's have trouble falling or staying asleep at night. Sleep problems can arise from Parkinson's motor or non-motor symptoms, medication side effects or other conditions that affect sleep."1

 

Cambridge Sleep Sciences has developed SleepHub®, a device that has been shown to improve sleep in people with insomnia, and will be working with Parkinson's Concierge to assess the efficacy of SleepHub® in people with Parkinson's prior to undertaking formal clinical trials.

 

Dr Chris Dickson, Executive Chairman of Cambridge Sleep Sciences, said: "People living with Parkinson's commonly experience disrupted sleep, and when Parkinson's Concierge advised us of anecdotal reports that SleepHub® had improved sleep in some of their members, we wanted to explore this further. Parkinson's Concierge, with their global community of members, made the natural partnership with which to investigate the potential benefits."

 

SleepHub® is the result of more than a decade of research and development. Users are helped to achieve quality sleep through scientifically formulated sounds, delivered using a pair of premium speakers, that use specific beats and pulses to modulate sleep patterns.

 

Parkinson's Concierge provide support to people affected by Parkinson's. There are 147,000 people in the UK with Parkinson's and 10 million worldwide.

 

Charlotte Allen and Russ Bradford, Co-Founders of Parkinson's Concierge, said: "We are very excited by our partnership with Cambridge Sleep Sciences and have high hopes for SleepHub® improving the lives of many people living with Parkinson's. At Parkinson's Concierge we always seek out products and services, gadgets, tech and AI solutions which can benefit people living with this condition. We are extremely optimistic, having tested SleepHub® for about a month now, that this could have an effect on improving the other symptoms people live with as well for our Global Parkinson's Community."

 

ENDS

 

 

1 Michael J. Fox Foundation: Fatigue & sleep 

 

Enquiries:

 

The Barkby Group PLC

Charles Dickson, Executive Chairman

Douglas Benzie, Chief Financial Officer

 

finnCap Ltd (Nomad and Broker)

+44 (0) 20 7220 0500

Carl Holmes/Simon Hicks (corporate finance)

Tim Redfern/Richard Chambers (ECM)

 

Camarco (Financial PR)

+44 (0) 20 3757 4994

Jennifer Renwick/Jake Thomas

 

 

About The Barkby Group Plc:

The Barkby Group PLC is a diversified group of high growth, high quality businesses run by an entrepreneurial and experienced management team. The existing wholly owned businesses within Barkby include; Commercial Property Development, Barkby Hospitality (comprising Barkby Pubs and Workshop Coffee) and Centurian Automotive.

 

In addition to these businesses, Barkby Life Sciences has invested in Verso Biosense (formerly known as Vivoplex), a digital health company aiming to transform Women's Health with precision medicine, and it has signed an agreement with Cambridge Sound Technologies UK Ltd for the exclusive design of, and acquisition of the intellectual property rights related to, a device to improve and facilitate natural sleep.

 

Barkby's strategy is to accelerate and maximise opportunities within its existing businesses as well as continue to source and invest in cash generative, growth businesses with the ability to disrupt.

About Cambridge Sleep Sciences Ltd

Cambridge Sleep Sciences Ltd, part of the Life Sciences division of The Barkby Group Plc, develop technology which improves natural sleep. Using the principles of neuroscience and cutting-edge technology to enhance brain activity during sleep, they develop innovative products that improve quality of life and re-energise lives.

 

The company prides itself on delivering the first neuroscience-based sleep product, SleepHub®, to help improve and facilitate natural sleep.

 

Find out more at: www.cambridgesleepsciences.com

 

About Parkinson's Concierge

Parkinson's Concierge are Parkinson's experts and advisory consultants, connectors and awareness creators of living with Parkinson's.

 

The organisation develops relationships & long term partnerships with organisations who can make change happen - supporting them to develop and deliver products and services which improve the quality of life for people living with Parkinson's.

 

Parkinson's Concierge have created a global affiliate healthcare platform which connects charities, partners and leading global medical professionals to each other and the Parkinson's community.

 

Find out more at: https://parkinsonsconcierge.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABBLLFFXLFBBB
12
Date   Source Headline
30th Jan 20246:03 pmRNSChange of Name to Roadside Real Estate plc
2nd Jan 20247:00 amRNSResult of General Meeting
19th Dec 202311:15 amRNSUpdate on debt refinancing and CSS
15th Dec 20237:00 amRNSFirst joint venture acquisition
13th Dec 20235:39 pmRNSPosting of Circular and Notice of General Meeting
4th Dec 20237:00 amRNSIntention to refinance debt facilities
7th Nov 20237:00 amRNSPractical completion of second Roadside asset
31st Oct 20237:00 amRNSFormation of Roadside Real Estate Joint Venture
29th Sep 20237:00 amRNSTrading update
19th Sep 20237:00 amRNSCSS Announces Licensing Deal with Mammoth
11th Sep 20237:00 amRNSResponse to media speculation re CSS
1st Aug 20237:00 amRNSDisposal of Workshop Coffee
14th Jun 20237:42 amRNSCSS announces new licensing agreement
9th Jun 20237:00 amRNSPub portfolio update
6th Jun 20237:00 amRNSMajor licensing deal for Cambridge Sleep Sciences
31st May 20237:00 amRNSPractical completion of first Roadside asset
15th May 20237:00 amRNSBoard Update, Equity Issue & Total Voting Rights
31st Mar 20237:00 amRNSInterim results
22nd Feb 20235:26 pmRNSResult of AGM
16th Jan 20237:00 amRNSNotice of AGM & Debt Facility Drawing
30th Dec 20227:01 amRNSFinal results for the year ended 2 July 2022
30th Dec 20227:00 amRNSRevised debt facility
28th Nov 20227:00 amRNSTrading and Strategy Update
25th Nov 20227:00 amRNSAcquisition of the Eliot Arms
7th Sep 20225:48 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSTrading and Strategy Update
21st Jun 20223:19 pmRNSDirector/PDMR Shareholding
11th May 20225:21 pmRNSHolding(s) in Company
26th Apr 20227:00 amRNSExchange of Contracts at Saffron Walden, Essex
1st Apr 20227:00 amRNSAcquisition of The Coach and Horses
30th Mar 20227:20 amRNSInterim Results
4th Mar 20226:09 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSAppointment of Group Property Director
2nd Mar 20227:00 amRNSVerso Biosense completes clinical study
1st Mar 20227:00 amRNSBoard Update
8th Feb 20225:35 pmRNSResult of AGM
3rd Feb 20223:33 pmRNSIssue of Equity and Total Voting Rights
25th Jan 20227:00 amRNSCambridge Sleep Sciences Announces New Partners
18th Jan 20227:00 amRNSVerso Biosense study nears completion
13th Jan 20227:00 amRNSPosting of Annual Report & Notice of AGM
24th Dec 20217:00 amRNSFinal Results for the Year Ended 1 July 2021
20th Dec 20212:06 pmRNSSecond Price Monitoring Extn
20th Dec 20212:00 pmRNSPrice Monitoring Extension
17th Dec 20217:00 amRNSExchange of Contracts in Swindon, Wiltshire
27th Oct 20214:41 pmRNSSecond Price Monitoring Extn
27th Oct 20214:35 pmRNSPrice Monitoring Extension
27th Oct 20212:05 pmRNSSecond Price Monitoring Extn
27th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Oct 202111:05 amRNSSecond Price Monitoring Extn
27th Oct 202111:00 amRNSPrice Monitoring Extension
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.